Meryem Yilmaz Kaysin

Meryem Yilmaz Kaysin

Auto-generated profile, based on publicly available information

Meryem Yilmaz Kaysin

Physical Medicine and Rehabilitation Department, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
OIOzge Gulsum Illeez
Ozge Gulsum Illeez
KOKubra Neslihan Kurt Oktay
Kubra Neslihan Kurt Oktay
IAIlknur Aktas
Ilknur Aktas
FOFeyza Unlu Ozkan
Feyza Unlu Ozkan
TNTuba Nazligül
Tuba Nazligül
PAPinar Akpinar
Pinar Akpinar
This study aimed to investigate the effects of duloxetine and pregabalin primarily on pain and functional status in patients with knee osteoarthritis and secondarily on quality of life, depression, anxiety, and sleep disturbance. A total of 66 patients with knee osteoarthritis were randomized to use duloxetine or pregabalin. Patients were evaluated by Visual Analog Scale, Neuropathic Pain Diagnostic Questionnaire, Western Ontario and McMaster University Osteoarthritis Index, Short Form-36, Beck Depression Inventory, Beck Anxiety Inventory, and Pittsburg Sleep Quality Index before the treatment and after 4 and 12 weeks of treatment. Improvements occurred in Visual Analog Scale, Neuropathic Pain Diagnostic Questionnaire, Western Ontario and McMaster University Osteoarthritis Index, Short Form-36 (with an exception of the mental health subgroup scores in duloxetine-treated group), Beck Depression Inventory, and Beck Anxiety Inventory scores in both groups from 4 weeks after baseline. Pittsburg Sleep Quality Index total scores and SF-36 mental health subgroup scores started to improve on the 4th and 12th weeks in pregabalin- and duloxetine-treated groups, respectively. Osteoarthritis pain, a complex outcome with nociceptive and neuropathic components, leads to central sensitization in a chronic phase. Using centrally acting drugs in the control of pain and associated symptoms would increase the probability of treatment success.

25 May 2024 in Integrative Medicine Research
Verified
Journal Article
Open access
DKDuygu Silte Karamanlioglu
Duygu Silte Karamanlioglu
MKMeryem Yilmaz Kaysin
Meryem Yilmaz Kaysin
FBFeyza Akan Begoğlu
Feyza Akan Begoğlu
PAPinar Akpinar
Pinar Akpinar
FOFeyza Unlu Ozkan
Feyza Unlu Ozkan
IAIlknur Aktas
Ilknur Aktas
Subacromial impingement syndrome (SIS) is the most common cause of shoulder pain. Acupuncture is a traditional medicine that is effective on pain. This study aimed to evaluate the effect of acupuncture treatment on pain, function, range of motion (ROM) and quality of life compared to sham acupuncture in patients diagnosed with SIS. A randomized, prospective, double-blinded, sham-controlled trial was conducted. In acupuncture group 40 participants received acupuncture treatment plus exercise therapy while in control group 40 participants received sham acupuncture plus exercise therapy. Primary outcomes included pain-rest, activity and night pain. Secondary outcomes included function [Shoulder Pain and Disability Index (SPADI) and The Disabilities of the Arm, Shoulder and Hand Score (Quick DASH)], ROM, and quality of life [The Western Ontario Rotator Cuff Index (WORC)] in patients with SIS. Both groups had significant improvements for pain-rest, activity night pain scores, SPADI, Quick DASH and WORC after treatment and at the first month follow-up. Significant improvements were recorded in the acupuncture group for all ROM after treatment and at the first month follow-up while in control group only in passive internal rotation. Acupuncture group had better improvements for Quick DASH, WORC and all ROM parameters after the treatment, as well as for all parameters except pain-night and passive flexion at the first month follow-up. This study suggest that acupuncture treatment is a safe, effective and non-invasive treatment option in patients with SIS. The study protocol is registered at clinicaltrials.gov (NCT05794633).

1 September 2022 in Journal of Surgery and Medicine
Verified
Journal Article
Open access
PDF file
MKMeryem Yilmaz Kaysin
Meryem Yilmaz Kaysin
İAİlknur Aktaş
İlknur Aktaş
FÖFeyza Ünlü Özkan
Feyza Ünlü Özkan
IZİrem Buse Kurucu Zeytin
İrem Buse Kurucu Zeytin
Background/Aim: Denosumab is a human monoclonal antibody that binds to the receptor-activated nuclear factor kappa beta ligand (RANKL). Densosumab leads to a reduction in bone resorption by inhibiting RANKL and has been approved for treating postmenopausal osteoporosis (OP). The present study investigated real life data by evaluating the demographic data of postmenopausal patients with OP who received denosumab treatment and the changes in dual energy x-ray absorptiometry (DEXA) parameters before and after denosumab treatment. Methods: This retrospective cohort study included 49 postmenopausal female patients followed in our OP outpatient clinic who were treated with 60 mg subcutaneous denosumab every six months for at least 12 months. The study retrospectively analyzed and recorded patient age, body mass index, age of menopause, fracture history, antiresorptive and/or anabolic drug treatment history, and pre- and post-denosumab T-scores in addition to L1–4, femoral neck, and total hip bone mineral densities (BMDs) on DEXA scans. The changes that occurred before and after the treatment in addition to those that occurred after the treatment based on whether previous anabolic or antiresorptive agents had been used were statistically compared. Results: The L1–4 and total hip T-scores and L1–4 and total hip BMD values measured prior to denosumab treatment showed a statistically significant increase after denosumab treatment (P < 0.001, P = 0.002, P = 0.028, and P = 0.002, respectively). No statistically significant changes in the femoral neck T-score and BMD after denosumab treatment compared to that before denosumab use (P = 0.056 and P = 0.138, respectively) were found. Furthermore, no statistically significant difference between the pre- and post-denosumab DEXA parameters in the patients who used antiresorptive agents and those who did not (P > 0.05) was found. Additionally, pre- and post-denosumab parameters were not statistically significantly different between those who received and did not receive anabolic therapy before denosumab (P > 0.05). Conclusion: Denosumab treatment for postmenopausal OP leads to a significant increase in lumbar and total hip T-scores and BMDs. '+st+' Armas LA, Recker RR. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinology and Metabolism Clinics of North America. Endocrinology and Metabolism Clinics. 2012 Sep 1;41(3):475-86. DOI: https://doi.org/10.1016/j.ecl.2012.04.006 Kuru P, Akyüz G, Cerşit HP, Çelenlioğlu AE, Cumhur A, Biricik S, et al. Fracture history in osteoporosis: risk factors and its effect on quality of life. Balkan Medical Journal. 2014 Dec;31(4):295-301. DOI: https://doi.org/10.5152/balkanmedj.2014.13265 Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporosis International. 2012 Mar 1;23(3):949-55. DOI: https://doi.org/10.1007/s00198-011-1655-5 Aziziyeh R, Perlaza JG, Saleem N, Kirazlı Y, Akalın E, McTavish RK, et al. The burden of osteoporosis in Turkey: a scorecard and economic model. Archives of Osteoporosis. 2020 Dec;15(1):128. DOI: https://doi.org/10.1007/s11657-020-00801-9 Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019 Jan 18;30(1):3-44. DOI: https://doi.org/10.1007/s00198-018-4704-5 Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine. 2009 Aug 20;361(8):756-65. DOI: https://doi.org/10.1056/NEJMoa0809493 McClung MR. Denosumab for the treatment of osteoporosis. Osteoporosis and Sarcopenia. 2017 Mar 1;3(1):8-17. DOI: https://doi.org/10.1016/j.afos.2017.01.002 Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The Lancet Diabetes and Endocrinology. 2017 Jul 1;5(7):513-23. DOI: https://doi.org/10.1016/S2213-8587(17)30138-9 Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. The Journal of Clinical Endocrinology and Metabolism. 2020 Mar;105(3):587-94. DOI: https://doi.org/10.1210/clinem/dgaa048 Hadji P, Papaioannou N, Gielen E, Tepie MF, Zhang E, Frieling I, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporosis International. 2015 Oct 1;26(10):2479-89. DOI: https://doi.org/10.1007/s00198-015-3164-4 Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporosis International. 2015 Jan 1;26(1):361-72. DOI: https://doi.org/10.1007/s00198-014-2871-6 Cairoli E, Palmieri S, Goggi G, Roggero L, Arosio M, Chiodini I, et al. Denosumab or oral bisphosphonates in primary osteoporosis: a ‘real-life’ study. Journal of Endocrinological Investigation. 2018 Aug 1;41(8):1005-13. DOI: https://doi.org/10.1007/s40618-018-0829-9 Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki...